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Introduction
Due to its occurrence and poor prognosis, pancreatic
cancer is the malignancy which takes the large death
toll. Five-year survival rate approaches 25% if the
tumor is not advanced and can be surgically removed,
otherwise it is only 5%. Only 10% of patients are 
diagnosed with the early-stage resectable disease [1].
Early detection is one of the clues for the improve-
ment in survival of pancreatic cancer patients. Until
now, there is no reliable screening method, moreover,
the diagnostic process is of limited performance.
Imaging modalities like helical computed tomography,
magnetic resonance imaging or endoscopic ultrasound
have the sensitivity up to 95% in detection of small
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Abstract: The aim of the study was to analyze the gene expression profile of pancreatic cancer to derive novel molecular
markers of this malignancy. The snap-frozen or RNA-later preserved samples of 18 pancreatic adenocarcinomas, 5 chronic
pancreatitis cases and 6 specimens of grossly normal pancreas were used for microarray analysis by HG-U133 Plus 2.0
oligonucleotide Affymetrix arrays. Validation was carried out by real-time quantitative PCR (Q-PCR) in the set of 66 sam-
ples: 31 of pancreatic cancer, 14 of chronic pancreatitis and 21 of macroscopically unchanged pancreas. By Principal Com-
ponent Analysis of the microarray data we found a very consistent expression pattern of normal samples and a less homog-
enous one in chronic pancreatitis. By supervised comparison (corrected p-value 0.001) we observed 11094 probesets dif-
ferentiating between cancer and normal samples, while only seventy six probesets were significant for difference between
cancer and chronic pancreatitis. The only gene occurring within the best 10 genes in both comparisons was S100 calcium
binding protein P (S100P), already indicated for its utility as pancreatic cancer marker by earlier microarray-based studies.
For validation we selected two genes which appeared as valuable candidates for molecular markers of pancreatic cancer:
neuroblastoma, suppression of tumorigenicity 1 (NBL1) and anillin (ANLN). By Q-PCR, we confirmed statistically signif-
icant differences in these genes with a 9.5 fold-change difference between NBL1 expression in cancer/normal comparison
and a relatively modest difference between cancer and pancreatitis. For ANLN even more distinct differences were observed
(cancer/normal 19.8-fold, cancer/pancreatitis 4.0-fold). NBL1 and anillin are promising markers for pancreatic carcinoma
molecular diagnostics.
Key words: pancreatic cancer, oligonucleotide microarrays, real-time quantitative PCR, NBL1 gene, anillin (ANLN) gene
tumors, but the discrimination between benign and
malignant masses is often very difficult. Fine needle
aspiration biopsy is only between 50-70% accurate in
determining whether the tumor is benign or malignant.
There are two reasons limiting the efficiency of fine
needle aspiration: sampling of tumor by the needle and
the sensitivity of pathological examination of the spec-
imen. The latter aspect could be significantly
improved by either 1) introducing immunohistochem-
ical markers to aid the diagnosis of pathologist or 2)
supporting the pathological review by multi-gene
measurement. The most probable is merging of both
approaches, but until now it was limited by the insuf-
ficient accuracy of existing protein markers and rela-
tive paucity of multi-gene classifiers, able to efficient-
ly discriminate low number of cells in regard to their
malignancy.
Both the improvement of the efficacy of pathologist
and the creation of complex diagnostic tests for pan-
creatic cancer rely on the powerful molecular markers.
Until now, several microarray experiments have been
carried out to analyze differences between the tran-
scriptome of pancreatic cancer and benign diseases
(summarized in [2-4]). Still, these analyses did not
result in any major progress in clinical diagnostics of
pancreatic cancer, probably due to the relative insuffi-
ciency of the existing molecular markers. Some of the
genomic profiling studies were carried out by early
generation of microarrays; also, not always the techni-
cal drawbacks have been omitted. Even more difficult
than in other cancers, obtaining of good quality RNA
from pancreatic tissue, especially normal pancreas, is
often compromised by the high activity of pancreatic
enzymes and the resulting large RNA degradation. 
The real power of microarray analyses will appear
if several studies carried out independently by differ-
ent groups lead to the specification of the panel of con-
sensus markers. The aim of the present study, based on
gene expression profiling, was to delineate novel
molecular markers for pancreatic carcinoma, suitable
for further diagnostic applications.
Materials and methods
Tissues samples. In gene expression measurements we used snap-
frozen or RNA-later preserved samples collected from 66 patients
operated on in Dept. of Digestive Tract Surgery of Silesian Medi-
cal University, among them 61% males and 39% females. Within
this group there were 31 patients with pancreatic cancer and 14
patients with chronic pancreatitis. In 21 patients macroscopically
unchanged pancreatic tissue (normal or adjacent to diseased
region) was collected.
RNA samples. Total RNA was isolated from approx. 30-50 mg of
sample by Chomczynski-Sacchi method, followed by RNA clean-
up on RNeasy Mini columns (Qiagen). 
Microarray preparation and analysis. For microarray investiga-
tion, samples of the best RNA quality, as assessed  by Agilent 2100
Bioanalyzer, were used: 18 pancreatic adenocarcinomas, 5 chronic
pancreatitis cases and 6 specimens collected from microscopically
unchanged pancreas. cDNA synthesis was carried out from 5µg of
total RNA (GeneChip® Expression 3' Amplification One-Cycle
cDNA Synthesis Kit, Affymetrix), then in vitro transcription was
performed as described by microarray manufacturer (GeneChip®
Expression 3' IVT Labeling Kit, Affymetrix). cRNA was
hybridized to Human Genome U133 Plus 2.0 microarray, measur-
ing approx. 38 500 human transcripts (Affymetrix). Arrays were
scanned in GeneChip Scanner 3000 (Affymetrix). The whole pro-
cedure was carried out according to the manufacturer's protocol.
The obtained dataset was pre-processed using GC-RMA method.
Unsupervised data-mining was carried out by Principal Compo-
nent Analysis method (GeneSpring, Agilent). Gene selection was
carried out by class comparison method, as implemented in limma
Bioconductor package (with Benjamini-Hochberg False Discovery
Rate estimation) [5]. 
RT-PCR. For real-time quantitative PCR (Q-PCR) cDNA synthe-
sis was carried from 1 µg of total RNA (Omniscript, Qiagen), the
reaction was performed on Applied Biosystems SDS 7700 machine
with Universal Probe Library fluorescent probes (Roche), with
amplicon design done by web application provided by manufac-
turer. We analyzed four reference genes: ATP6V1E1, EIF3S10,
HADHA, UBE2D2 and normalized the obtained result to the ref-
erence index obtained by geNorm software [6]. 
Ethical issues. All samples were collected upon approval by Ethics
Committee of Silesian Medical University.
Statistical analysis. Expression data were analyzed by Statistica
6.0 package (Statsoft) by non-parametric Kruskall-Wallis test.
Results
We performed unsupervised assessment of the
microarray dataset by Principal Component Analysis
method (see Fig. 1A and 1B). We have found that the
major source of variability is the difference between
cancer and normal specimens (not shown). When the
analysis was carried out only on cancer and normal
samples, the cluster of normal pancreas showed 
a very homogenous pattern of expression, clearly
delineating itself within the first Principal Compo-
nent (Fig. 1A). Unsupervised analysis of cancer sam-
ples and chronic pancreatitis specimens showed
much less homogeneity within chronic pancreatitis
group, and much smaller distance between the two
clusters (Fig. 1B). Moreover, the difference between
pancreatic cancer and chronic pancreatitis did not
allow to classify these two groups based on the first
Principal Component; it was necessary to use two
major sources of variability to differentiate between
both classes.
In the next step, we carried out the supervised com-
parison of gene expression between normal samples of
pancreatic tissue and tumor samples from patients with
pancreatic cancer. We noticed a very large number of
differentiating genes: from 54675 probesets on HG-
U133 Plus 2.0 microarray, 29208 of them showed cor-
rected p-value below 0.05. More than 11 000 probesets
were found to exhibit difference of high significance,
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with corrected p-value lower than 0.001. Three most
significant genes were found with false discovery rate
approx. 10-15, confirming the high reliability of
observed differences in gene expression (Table 1).
Comparison between pancreatic cancer and samples
from patients with chronic pancreatitis resulted in the
lower number of significant probesets. The limit of cor-
rected p-value of 0.05 was met by 1332 transcripts.
Seventy six of them showed corrected p value <0.001,
with three most significant transcripts at similar level of
significance like in cancer-normal comparison (10-15)
(Table 2). The results obtained in supervised approach
were consistent with the unsupervised analysis: chron-
ic pancreatitis samples were much more similar to pan-
creatic cancer, while the difference between cancer
and normal pancreas was of very large magnitude.
The genes most over-expressed in cancer, com-
pared to normal pancreas tissue, were collagen, type I,
alpha 1 (signal log ratio SLR 3.99, i.a. more than 15-
fold increase), S100 calcium binding protein P (SLR
8.97, more than 500-fold increase), periostin (SLR
8.16), neuroblastoma, suppression of tumorigenicity 1
(NBL1, SLR 5.12, 34.7-fold increase in cancer), cofil-
in 1 (non-muscle) and S100 calcium binding protein
A6 (calcyclin, SLR 5.08). 
Among transcripts down-regulated with high sig-
nificance in cancer in comparison to normal pancreas
there was the most significant gene obtained in this
comparison, coiled-coil domain containing 110, with
22-fold decrease of expression, cyclin-dependent
kinase 2-interacting protein and one less characterized
transcript.
The analysis of genes differentiating between pan-
creatic cancer and chronic pancreatitis pointed out the
S100P, the only gene occurring within the first 10 tran-
scripts in both comparisons and most significantly
over-expressed in cancer when compared to pancreati-
tis specimens. More than 370-fold increase of S100P
expression in pancreatic cancer versus chronic pancre-
atitis is of similar range like the one observed in com-
parison to normal specimens. The remaining genes
showed a lower signal log ratio values, ranging from
4.88 for SERPINB5 (serpin peptidase inhibitor, clade
B, member 5) to 2.94 for KCNN4 (potassium interme-
diate/small conductance calcium-activated channel,
subfamily N, member 4). Only one of selected genes
(ADH1A, alcohol dehydrogenase 1A, alpha polypep-
tide) was down-regulated in cancer, when compared to
chronic pancreatitis.
Two genes were selected for validation by quantita-
tive real-time PCR: neuroblastoma, suppression of
tumorigenicity 1 (NBL1) and anillin (ANLN). For
both genes we confirmed the statistically significant
differences in gene expression between pancreatic can-
cer, chronic pancreatitis and normal pancreas
(p<0.0001, Kruskall-Wallis ANOVA), for data normal-
ized by geNorm (Table 3 and 4) and also for raw,
unnormalized data (not shown). There was large, 9.5-
fold change difference between NBL1 expression in
cancer/normal comparison, while the observed differ-
ence between cancer and pancreatitis was of low fold-
change and of large overlap in gene expression (Fig.
2). For ANLN a gradual increase in expression from
normal samples by chronic pancreatitis to large values
in pancreatic cancer was observed (cancer/normal
19.8-fold, cancer/pancreatitis 4.0-fold). In post-hoc
inter-group comparisons, both genes differentiated
between cancer/normal (p<0.000001) and cancer/pan-
creatitis (p<0.000001 for ANLN and p=0.000001 for
NBL1); for NBL1 there was also a moderate differ-
ence between normal specimens and pancreatitis
(p=0.02), while for ANLN there was no significant dif-
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Fig. 1 Principal Components Analysis of pancreatic cancer (red) vs normal pancreas (green, Fig. 1A) and pancreatic cancer vs chronic pan-
creatitis (yellow, Fig. 1B). First two principal components are shown on X and Y axes. 
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Table 1. Pancreatic cancer vs normal pancreas 10 top differentiating genes, based on microarray results. 
Table 2. Pancreatic cancer vs chronic pancreatitis 10 top differentiating genes, based on microarray results.
ference between these two groups, probably due to low
number of samples in both groups, with moderate fold
change. 
Discussion
In our study we analyzed differences in gene expres-
sion between pancreatic cancer, chronic pancreatitis,
the important benign disease often mimicking clinical-
ly pancreatic carcinoma, and normal pancreas tissue.
In our opinion it is very important to base the marker
selection process on both comparisons, as the first one
is the most often occurring in clinical setting, while the
second one is very important from the point of view of
potential inappropriate sampling. Its inclusion allows
the correct discrimination of normal pancreas which
may be erroneously obtained during the diagnostic
process.
The comparison of both gene lists, the one obtained
for pancreatic cancer vs normal pancreas and the other
obtained for pancreatic cancer vs chronic pancreatitis,
revealed within the top differentiating transcripts only
one common gene, S100P. This gene has been indicat-
ed by Logsdon et al for its gene expression up-regula-
tion in pancreatic cancer already in 2003 [7]. Further
studies have indicated that it is up-regulated mainly in
pancreatic cancer cells, early in pancreatic canceroge-
nesis and may be applied in the immunohistochemical
diagnostics (8-11).
Looking for novel markers, for further validation we
selected two genes: NBL1, optimally differentiating
pancreatic cancer from normal pancreas, and anillin
which appeared as a potential good marker differentiat-
ing between chronic pancreatitis and cancer. The
obtained results lead to the conclusion that especially
anillin is a very good discriminator for both groups.
Anillin gene (HUGO name: anillin, actin binding
protein, abbreviated ANLN, also known as Drosophila
Scraps homolog,  DKFZp779A055), located on chro-
mosome 7p14.2, 84 kb in length, is transcribed from
24 exons, with 20 splice variants (reference transcript
NM_018685.2). It encodes 1124 aminoacid protein
with estimated molecular weight 123 477
(NP_061155.2, UniProt/Swiss-Prot Q9NQW6). Dur-
ing interphase, anillin is preferentially localized in the
cell nucleus, in anaphase it concentrates to form the
contractile ring. It interacts with F-actin and regulates
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Table 3. Comparison between normal (N), chronic pancreatitis (P) and cancer samples from pancreatic carcinoma (T) by real-time quan-
titative PCR for ANLN and NBL1 gene. Mean, median and quartile values are given. Presented data are absolute, given in relation to the
expression of both genes in Stratagene Reference Total RNA, after normalization by geNorm-obtained index (expression of 1 is equal to
the expression of each gene in reference RNA).
Fig. 2 Quantitative real-time PCR
measurement of gene expression for
NBL1 (A) and ANLN (B) genes in
normal pancreas (N), chronic pan-
creatitis (P) and cancer sample (T)
from patients with pancreatic cancer.
Values 
Table 4. Comparison between normal, chronic pancreatitis and
cancer samples from pancreatic carcinoma by real-time quantita-
tive PCR for ANLN and NBL1 gene. Ratios of mean values are
presented.
the contractile activity of myosin II. It is required for
cytokinesis as an essential element of cleavage furrow
formation, and suggested to be a pivotal organizer of
the cytokinetic machinery [12]. 
Anillin is a gene expressed at the highest levels in
brain, but rather ubiquitously present in various tis-
sues. It is present in developing and in mature organs.
As its expression is highly increased in dividing cells
(it is present in mitosis and during S and G2 phases,
low in G1 phase), some of its tissue specificity may be
related to the tissue proliferative potential (high in pla-
centa, testis, at intermediate level in intestine, ovary,
thymus), but it may be in other way related to the func-
tion of cytoskeleton (very high in brain, moderate
expression in skeletal muscles).
Anillin gene has been found to be over-expressed
in breast tumors [13], endometrial carcinomas [14]
and gastric cancer [15]. Hall et al. [16] analyzed
anillin expression by electronic northern blot and
oligonucleotide microarrays in a huge dataset of more
than 7 thousand samples and found that anillin mRNA
level was higher in cancers than normal tissues, with
moderate correlation to Ki67 gene expression. They
also found that anillin expression showed a tumor
progression-related pattern of expression in breast,
ovarian, kidney, colorectal, hepatic, lung, endometrial
and pancreatic cancer.
Simultaneously, an over-expression of ANLN was
found to be associated with pulmonary carcinogenesis
[17], based on earlier gene expression data for lung can-
cer [18], and it has been experimentally demonstrated
that anillin expression is related to disease aggressive-
ness by interaction with RhoA (small GTPase acting as
a key regulator of contractile-ring formation during
cytokinesis, and known to directly interact with anillin
[19]). By immunohistochemistry the authors demon-
strated the association of ANLN expression with the
poor survival in non-small cell lung cancer. This was
further confirmed by Skrzypski et al.  (20), who
assessed ANLN expression in early-stage lung cancer.
NBL1 gene (NM_005380.4, HUGO name: neurob-
lastoma, suppression of tumorigenicity 1, also known
as N03, DAN, DAND1, MGC8972 or D1S1733E), is
located on chromosome 1p36.13. It was identified as a
putative tumor suppressor gene in transformed fibrob-
lasts model and was mapped to the putative neuroblas-
toma tumor suppressor locus [21,22].
It encodes 180 aminoacid secreted protein
(NP_005371.1) which is bone morphogenetic proteins
antagonist, blocking BMP interaction with their recep-
tors. NBL1 was able to stimulate differentiation of
neuroblastoma cells in culture in the presence of
retinoic acid [23]. The growth suppressive activity has
been also noted in sarcoma cells [24], later on it has
been shown that NBL1 is engaged in osteoblast dif-
ferentation [25]. 
NBL1-mediated antagonism of Bmp pathway in mice
is important for brain development (26). In pituitary
gonadotrope cells, NBL1 is stimulated by GnRH [27]; it
inhibits monocyte chemotaxis in vitro (28). In dorsal root
ganglia of rat, it may act as neurotransmitter [29].
The fact that previously NBL1 has been attributed
the role of tumor suppressor in neuroblastoma some-
what contradicts our observations that it is highly over-
expressed in pancreatic cancer. However, its role in
neuroblastoma seems to be controversial: it was
excluded based on LOH analysis [30] and more recent
data of the same group point out other more probable
candidates in the same chromosomal region [31,32].
While anillin has been listed by Hall et al. [14] as
the potential marker in pancreatic carcinoma, NBL1
has not gained any focused attention in this context up
to now. Both genes were listed by landmark studies of
Iacobuzio-Donahue: NBL1 from cDNA platform
analysis [33] while ANLN in the study integrating
oligonucleotide, cDNA and SAGE analysis [34]. How-
ever, from that time they were not further investigated.
Our results indicate that both of them are good candi-
dates for further studies as markers of pancreatic
malignancy and simultaneuously point out on anillin
for its potential to discriminate between cancer both
from normal pancreas and chronic pancreatitis. We
consider that the occurrence of both genes in two inde-
pendent microarray datasets, supported by the RNA
level Q-PCR validation should be a rationale to use
them as RNA markers independently from the further
(necessary) confirmation of their diagnostic usefull-
ness by immunohistochemistry. 
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